Roche Tries Again With Failed Huntington’s Drug Tominersen
Potential In Younger Adults
Executive Summary
Despite disappointment in its Phase III study, Roche is preparing a new trial of the antisense therapy in patients with a lower disease burden.
You may also be interested in...
Wave’s Huntington Drugs Wipe Out As Trials Run Aground
The company now turns to its next-generation Huntington drug, WVE-003.
Bavarian Nordic Rises As It Meets Demand For Monkeypox Vaccine
The Danish company has the world’s only licensed monkeypox vaccine and is now fielding enquiries from concerned governments from around the world.
Gene Therapy Development Should Involve Fewer Surprises, Says US FDA’s Marks
Regulators want to help smooth the process of bringing a gene therapy to market, hoping to iron out ‘surprises’ and even address reimbursement issues for the sake of patients.